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Objectives: To systematically review the published evidence regarding the association between Mg
intake and serum concentrations with MetS and, if possible, to summarize the results using a
meta-analysis.
Methods: PubMed, ISI Web of Science, Scopus, and Google Scholar were searched to identify related
articles. Fully adjusted odds ratios (ORs) of MetS in participants with the highest intake of Mg
compared with those who had the least consumption, and the mean difference in serum Mg levels
between patients with MetS and their controls were extracted for the meta-analysis.
Results: In total, 9 articles with 31 876 participants were included in the meta-analysis regarding
the association between dietary Mg intake and MetS, and 8 studies that assessed the mean level of
serum Mg in 3487 individuals with and without MetS were eligible. Our analysis found that higher
consumption of Mg is associated with lower risk of MetS (OR ¼ 0.73; 95% conﬁdence interval: 0.62,
0.86; P < 0.001); we also could ﬁnd a signiﬁcant but heterogeneous association between serum Mg
and MetS (mean difference: 0.19; 95% conﬁdence interval: 0.36, 0.03; P ¼ 0.023).
Conclusions: The present systematic review and meta-analysis found an inverse association be-
tween Mg intake and MetS. However, the inverse association for serum Mg levels was highly
heterogeneous and sensitive. The link between Mg status and MetS should be conﬁrmed by pro-
spective cohort studies controlling the association for other nutrients related to MetS risk.
 2016 Elsevier Inc. All rights reserved.Introduction diabetes mellitus, hypertension, dyslipidemia, and cardiovascu-Controversy exists about serum magnesium (Mg) concen-
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bargouei@gmail.com (A.lar diseases. MetS, a highly widespread disease among devel-
oped and developing populations [1], is characterized as a cluster
of risk factors that threat public health and increase disability,
mortality, and health-care costs [2]. On the basis of the Adult
Treatment Panel III (ATP III) guidelines, MetS is deﬁned as the
presence of three or more of the following characteristics: high
blood pressure, hyperglycemia, hypertriglyceridemia, low con-
centrations of high-density lipoprotein (HDL) cholesterol, and
abdominal obesity [3]. Regardless of its deﬁnition, MetS in-
creases the risk of diabetes and cardiovascular diseases [4].
Although the role of dietary ingredients is less understood,
dietary components are important in many chronic diseases
and it is believed that nutrients play important roles in the
N. Sarrafzadegan et al. / Nutrition 32 (2016) 409–417410development of MetS [5]. Mg is an essential nutrient that
particularly is found in green leafy vegetables, whole grains, le-
gumes, and nuts [6]. As the second intracellular cation in abun-
dance [7], Mg is a critical cofactor for hundreds of enzymatic
reactions, including energy metabolism, protein and nucleic acid
synthesis, and insulin secretion and action [8,9]. Previous studies
reported that Mg deﬁciency is frequently (25% to 47%) observed
in diabetic patients [10]. Rapidly growing evidence suggests that
dietary Mg has valuable effects, including regulation of systemic
inﬂammation [11] and hypertension [12], modiﬁcation of lipids
[13,14], glucose and insulin metabolism [15], improvement of
insulin sensitivity [16,17], and decreasing the risk of diabetes [6].
Reduced serum Mg concentrations and low intakes of Mg are
proposed to be associated with MetS, its components, and also
other chronic conditions such as insulin resistance [18], diabetes
mellitus [19], hypertension [8], dyslipidemia [20], and cardio-
vascular diseases [21]. Data about the association between Mg
status and MetS are conﬂicting. Some studies have shown a
negative association between Mg intake and MetS [22], whereas
others could not reach a signiﬁcant result [23]. We are aware of
two systematic review and meta-analyses that found an inverse
association between dietary Mg intake and MetS [24,25].
However, data about the association between serum Mg
concentrations andMetS aremore conﬂicting; for instance, some
studies concluded that serum Mg levels are lower in patients
with MetS compared with their controls [26,27], whereas other
studies reported a non-signiﬁcant association [28] or even
proposed that there may be a positive association between
serum Mg concentration and MetS [27].
Although some studies have reviewed the association
between dietary Mg intake and MetS, to the best of our knowl-
edge, no study has tried to summarize the published evidence
regarding the association between serum levels of Mg and MetS.
Therefore, the aim of the present study was to perform a
systematic review and if possible meta-analyses on the obser-
vational studies regarding the association between dietary or
serum Mg level and the likelihood of MetS.
Materials and methods
Search strategy
We focused on publications considering the association between dietary or
serum content of Mg and MetS. PubMed, ISI Web of Science, Scopus, and Google
Scholar were searched to identify related articles published up to February 2014.
The following keywords, which were selected from the medical subject headings
and other related terms, were used for the database search: “magnesium” OR
“Mg” OR “magnesium” in combination with “Metabolic Syndrome X” OR
“metabolic syndrome”OR “syndromeX.”No language or any other limitationwas
used in our literature search. Reference lists of related articles were considered
for other potentially related papers. Titles and abstracts were separately
reviewed by two authors (H.K.B., A.S.A.) to ﬁnd eligible articles for the present
study. Any inconsistency between search results was resolved by discussion with
the other authors (N.S., M.L.).
Inclusion criteria
Observational studies published in peer-reviewed journals and assessed the
association between Mg intake and MetS, or studies that compared serum levels
of Mg in patients with and without MetS were included in our systematic review.
Exclusion criteria
Studies that examined the association of Mg intake or serum levels of Mg
withMetS in participants with polycystic ovary syndrome [29], cardiac syndrome
[30], diabetes mellitus [31–33], or morbidly obese individuals [34] were excluded
from our study, because the risk estimates for becoming MetS for these partici-
pants are different from the normal population; furthermore, participants with
these conditions are more likely to change their diet to manage their disease andthis might confound the nutrient-disease associations. One study that did not
compare the Mg content of the whole diet was also excluded [35].
Data extraction
We extracted all relevant information from eligible articles, including ﬁrst
authors’ familyname, publicationyear,MetSdeﬁnition, studydesign, participants’
sex, age range, geographic location, total sample size, sample size in case and
control studies, Mg intake, and relative risks or odds ratios (ORs) of MetS for
comparison between the highest and lowest category of Mg intake inmodels that
had the highest number of adjusted variables in the statistical model. Further-
more,we extracted themean SDof serumMg levels from studies that compared
serum Mg levels between participants with MetS and their controls. Data
extraction and the quality assessmentwere completed by two authors (H.K.B. and
A.S.A.) to guarantee equality, and one of the authors entered all of the data (H.K.B.).
Most of the studies presented the serum Mg in mg/dL. For studies in which
Mg concentration was not shown in mg/dL, we changed other units, including
mg/L [27], mmol/L [28], and meq/L [36], to mg/dL.
Data analysis
The ORs and their 95% conﬁdence intervals (95% CIs) for comparing the
prevalence or the incidence of MetS between groups with the highest and lowest
Mg intake were used to calculate the log OR and its standard error (SE) as the
effect size to be included in meta-analysis [37]. Relative risks (RRs) were
considered as ORs when used in meta-analysis because only one study reported
RRs [38]. We calculated ORs and their 95% CIs if a study reported the number of
participants based on their Mg consumption strata. Eight studies also compared
mean  SD of serum Mg level in participants with MetS and their controls [20,
26–28,36,39–41]; therefore, we used them to calculate unstandardized mean
difference in serum Mg levels as effect size for another meta-analysis. Overall
effect was derived by using random effects model, which takes between-study
variations into account [37]. Statistical heterogeneity was assessed using
Cochran’s Q test and I2 [42]. Subgroup analysis and meta-regression were
incorporated to search about the possible sources of heterogeneity if needed.
Sensitivity analysis was used to explore the extent to which inferences might
depend on a particular study or a number of publications. Publication bias was
evaluated by looking over Begg’s funnel plots [43]. Formal statistical assessment
of funnel plot asymmetry was conducted using Egger’s regression asymmetry
test and Begg’s adjusted rank correlation test. Statistical analyses were conducted
using STATA version 11.2 (STATA Corp., College Station, TX, USA). P values less
than 0.05 were considered statistically signiﬁcant.
Results
Study characteristics
Our search retrieved 141 articles, of which 19 related articles
fulﬁlled our inclusion criteria [5,10,16,21,33,35,36,38,43–53]. One
study that compared mean Mg intake between patients with
MetS and controls (but not reported OR) was included in our
systematic review but not in the meta-analysis [54]. Another
study done by Mirmiran et al. [55] did not represent data on OR
forMetS based onMg intake groups; therefore, we asked authors
about data by three e-mails separated at least by 1 wk; however,
the authors could not provide the needed data; therefore, we
included this article in the systematic review but not in the
meta-analysis too. The ﬂow diagram of the study selection pro-
cess is illustrated in Figure 1.
Among the reviewed articles included in meta-analysis, ﬁve
were conducted in the United States [43,45–48]; two in Greece
[36,39]; two in Mexico [20,26]; one in Australia [28], China [27],
Taiwan [22], Italy [23], Brazil [41], South Korea [56], and Saudi
Arabia [57]; and three in Iran [40,51,55] (Tables 1 and 2). The
participants’ age ranged from 18 to 90 y and the study sample
size ranged from 117 to 11 686 participants, and totally 35 363
individuals participated in all studies. Among the 17 studies, 1
study was conducted entirely in women [38], 1 study in men
[27], and other studies reported the association for both women
and men. Characteristics of included studies that examined the
association for dietary and serum Mg levels are presented in
Tables 1 and 2, respectively.
Fig. 1. The study selection process. MetS, metabolic syndrome; PCOS, polycystic
ovary syndrome.
Table 1
Characteristics of studies investigating the association between dietary magnesium in
Author, year (country) Metabolic
syndrome
deﬁnition
Study design Sample size Age Sex
Bo et al., 2006
(Italy) [23]
ATP III Cross-sectional 1658 45–64 Both
Ford et al., 2007
(United States) [45]
ATP III Cross-sectional 7669 >20 Both
He et al., 2006
(United States) [46]
ATP III Cohort 4637 18–30 Both
Song et al., 2005
(United States) [38]
ATP III Cross-sectional 11686 >45 Fem
Noori et al., 2010
(Iran) [51]
ATP III Cohort 160 >18 Both
McKeown et al., 2008
(United States) [50]
ATP III Cross-sectional 535 >60 Both
Huang et al., 2012
(Taiwan) [22]
ATP III Cross-sectional 210 <65 Both
Morrell et al., 2012
(United States) [54]
AHA Cross-sectional 2722 18–24 Both
Mirmiran et al., 2012
(Iran) [55]
ATP III Cross-sectional 2504 18–74 Both
Choi and Bae, 2013
(South Korea) [56]
ATP III Cross-sectional 2084 >19 Mal
3052 >19 Fem
Al-Daghri et al., 2013
(Saudi Arabia) [57]
IDF Cross-sectional 185 19–60 Both
AHA, American Heart Association; ATP III, Adult Treatment Panel III; BMI, body mass
K, potassium; Na, sodium; OR, odds ratio; PUFAs, polyunsaturated fatty acids; RR, rel
N. Sarrafzadegan et al. / Nutrition 32 (2016) 409–417 411In total, 9 articles with 31 876 participants were included in
the meta-analysis regarding the association between dietary Mg
intake and MetS [22,23,38,45,46,50,51,56,57]. The results of our
analysis showed that higher consumption of Mg is associated
with lower risk of MetS (OR¼ 0.73; 95% CI: 0.62, 0.86; P< 0.001)
(Fig. 2). However, there was a slight level of heterogeneity be-
tween studies (Cochrane Q test, P ¼ 0.149, I2 ¼ 32.4%). When the
methodology of included studies was carefully reviewed, we
noticed that a study done byMcKeown et al. [50] used bodymass
index (BMI) higher than 31 kg/m2 for men and 27 kg/m2 for
women as an index for abdominal obesity, whereas other studies
deﬁned MetS based on ATP III; therefore, we removed this study
from our analysis and the heterogeneity signiﬁcantly decreased
(Cochrane Q test, P ¼ 0.429, I2 ¼ 0.5%), whereas the association
remained signiﬁcant (OR ¼ 0.78; 95% CI: 0.69, 0.88; P < 0.001)
(Fig. 3).
Our preliminary analysis on 8 studies [20,26–28,36,39–41],
which assessed themean serumMg in 3487 individuals with and
without MetS (Fig. 4), indicated that serum Mg level in MetS
participants is about 0.19 mg/dL lower compared with the
normal population (95% CI: 0.36, 0.03; P ¼ 0.023), but there
was a signiﬁcant heterogeneity between studies (Cochrane Q
test, P < 0.001, I2 ¼ 98.5%). Among included studies, two had
used International Diabetes Federation’s criteria [39,41] and one
had used Chinese Diabetes Society’s criteria [27] to deﬁne MetS,
and a study done by Guerrero-Romero and Rodriguez-Moran
[26] had excluded individuals with hypertension and diabetes
from the study population. Therefore, these four studies weretake and metabolic syndrome
Adjusted OR or RR Adjusted variables
1.03 (0.62, 1.70) Age, sex, BMI, smoking, alcohol, physical activity,
calories, fat, ﬁber
0.56 (0.34, 0.92) Age, sex, race, education, smoking, C-reactive
protein, alcohol, physical activity, family history of
coronary disease, vitamin and supplement intake,
diabetes history, fat, carbohydrates, ﬁber, total
energy
0.63 (0.47, 0.84) Age, sex, race, education, smoking, physical activity,
family history of diabetes, alcohol, BMI, ﬁber, PUFAs,
SFAs, CHO, total energy intake
ale 0.65 (0.52, 0.83) Age, calorie, smoking, physical activity, alcohol,
family history of myocardial infarction, fat,
cholesterol, folate, glycemic load
1.73 (0.38, 7.85) Age, sex, smoking, physical activity, dialysis mode,
dose of steroid, FH diabetes and stroke, calorie, BMI,
ﬁber
0.36 (0.19, 0.69) Age, sex, race, education, marital status, smoking,
alcohol, physical activity, BMI, calorie, SFA, lipid
medication, BP medication except for model with
BP
0.49 (0.17, 1.43) d
d d
d Age, sex, smoking, physical activity, ﬁber, SFAs, K,
Ca, Na, ﬁsh and food groups
e 0.81 (0.53, 1.23) Age
ale 0.90 (0.62, 1.30)
0.50 (0.25, 1.00) d
index; Ca, calcium; CHO, carbohydrate; IDF, International Diabetes Federation;
ative risk; SFAs, saturated fatty acids
Table 2
Characteristics of studies investigating the association between serum magnesium level and metabolic syndrome (MetS)
Author, year (country) Metabolic
syndrome
deﬁnition
Study design Sample
size
Age
(cases)
Age
(controls)
Sex No MetS serum mg,
mean  SD
MetS serum mg,
mean  SD
Adjusted
variable
Evangelopoulos et al.,
2008 (Greece) [39]
IDF Cross-sectional 117 67.0 65.0 Both 1.99  0.24
(n ¼ 35)
1.83  0.23
(n ¼ 82)
d
Ghasemi et al., 2010
(Iran) [40]
ATP III Cross-sectional 137 60–90 60–90 Both 2.16  0.03
(n ¼ 77)
2.08  0.03
(n ¼ 60)
Sex, creatinine,
high TG, high
WC, hypertension,
low HDL-C,
hyperglycemia,
diabetes
Guerrero-Romero and
Rodriguez-Moran, 2002
(Mexico) [26]
ATP III Case-control 576 42.3 41.5 Both 2.20  0.20
(n ¼ 384)
1.80  0.30
(n ¼ 192)
d
Guerrero-Romero and
Rodriguez-Moran, 2006
(Mexico) [20]
ATP III Case-control 441 44 43.0 Both 2.1  0.3
(n ¼ 294)
1.8  0.4
(n ¼ 147)
d
Kalaitzidis et al., 2005
(Greece) [36]
ATP III Cross-sectional 255 48.8 48.7 Both 2.04  0.36
(n ¼ 191)
1.92  0.36
(n ¼ 64)
d
Simmons et al., 2010
(Australia) [28]
ATP III Cross-sectional 1453 53 53 2.02  0.14
(n ¼ 1168)
2.02  0.17
(n ¼ 363)
d
Yu et al., 2012 (China) [27] CDS Cross-sectional 379 24–57 24–57 Male 1.93  0.28
(n ¼ 149)
2.09  0.28
(n ¼ 52)
d
Lima et al., 2009
(Brazil) [41]
IDF Cross-sectional 129 45.7  11.8 45.7  11.8 Both 2.43  0.43
(n ¼ 57)
1.80  0.18
(n ¼ 72)
d
ATP III, Adult Treatment Panel III; CDS, Chinese Diabetes Society; HDL-C, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; Mg, magnesium;
TG, triacylglycerol; WC, waist circumference
N. Sarrafzadegan et al. / Nutrition 32 (2016) 409–417412removed from our analysis, but the heterogeneity remained
signiﬁcant (Cochrane Q test, P ¼ 0.000, I2 ¼ 96.2%) (Fig. 5).
Moreover, removing these articles turned the association be-
tween serum levels of Mg and MetS into a non-signiﬁcant one
(mean difference [MD] ¼ 0.12; 95% CI: 0.28, 0.03; P ¼ 0.113).
Furthermore, we tried to ﬁnd the source of heterogeneity using a
subgroup analysis based on the participants’ age and sex, criteria
used to deﬁne MetS, study design, and country of origin. We also
incorporated meta-regression to examine if publication year and
participants’ mean age can describe the high level of heteroge-
neity between the included studies; however, none of these
methods were successful to ﬁnd the source of heterogeneity.
Sensitivity analysis found that none of individual studies
trying to examine the association between dietary or serumFig. 2. Meta-analyses of studies examining dietary magnesiumlevels of Mg and MetS could signiﬁcantly change the overall ef-
fects. Although Begg’s funnel plot for studies that reported the
ORs of Mg intake showed that the distribution of calculated ef-
fect sizes was slightly asymmetrical (Fig. 6A), the asymmetry
tests did not provide any evidence of publication bias (Begg’s
test, P ¼ 0.245; Egger’s test, P ¼ 0.140). Begg’s funnel plot for
studies that reported the serum Mg between patients with and
without MetS was also the same (Begg’s test, P ¼ 0.621; Egger’s
test, P ¼ 0.210) (Fig. 6B).
Discussion
The present systematic review and meta-analysis found that
increased Mg consumption is associated with lower risk of MetS.intake and metabolic syndrome. CI, conﬁdence interval.
Fig. 3. Meta-analyses of studies examining dietary magnesium intake and metabolic syndrome after removing study done by McKeown et al. [50], which used body mass
index higher than 31 kg/m2 for men and 27 kg/m2 for women as an index for abdominal obesity. CI, conﬁdence interval.
N. Sarrafzadegan et al. / Nutrition 32 (2016) 409–417 413Moreover, although the heterogeneity was high, our analyses
revealed that patients with MetS have lower levels of blood Mg
concentrations than healthy controls; however, this association
was not replicated whenwe excluded studies that used different
deﬁnitions other than ATP III for MetS. To the best of our
knowledge, there are two review articles published in 2014
regarding the association between Mg intake and MetS [24,25].
Ju et al. [24] showed an inverse dose-response association
among nine observational studies, whereas Dibaba et al. [25]
found the same relationship in six observational studies in
their analysis. In the present study we could ﬁnd 11 studies
regarding the association between dietary Mg intake and MetS
and included 9 studies in the meta-analysis. Furthermore, we
reviewed studies that examined serum Mg levels in association
with MetS and summarized their effect using a meta-analysis.
We could not include two studies [54,55] regarding the as-
sociation between dietary Mg intake and MetS because they didFig. 4. Meta-analyses of studies examining serum magnesiumnot provide the essential data. However, all these studies have
mentioned an inverse association between dietary Mg intake
andMetS in their results. Morrell et al. [54] compared individuals
with two or more criteria for MetS and participants without any
MetS criteria and found a signiﬁcant difference in their Mg intake
(251 versus 269 mg). Mirmiran et al. [55] also observed a nega-
tive association between dietary Mg and MetS Z-score in obese
individuals and high-ﬁber consumers, but this association was
not signiﬁcant in normal-weight participants or in people with
low ﬁber consumption. After adjustment for other covariates, no
signiﬁcant association was found between Mg intake and MetS.
This study indicated that the association between Mg intake and
MetS cannot be independent of ﬁber, calcium, and potassium
and other nutrients intake.
Although we found a strong inverse association between Mg
intake and the likelihood of MetS, we could not ﬁnd the same
association for serumMg levels whenwe pooled studies that hadlevel and metabolic syndrome. CI, conﬁdence interval.
Fig. 5. Meta-analyses of studies examining serum magnesium level and MetS after removing two studies that had used International Diabetes Federation’s criteria [37,40]
and one study that had used Chinese Diabetes Society’s criteria [24] to deﬁne MetS and a study done by Guerrero-Romero [26], which had excluded individuals with hy-
pertension and diabetes from the study population. CI, conﬁdence interval; MetS, metabolic syndrome.
N. Sarrafzadegan et al. / Nutrition 32 (2016) 409–417414used the same deﬁnitions for MetS. A previous meta-analysis
reported that Mg supplementation signiﬁcantly increased
serum or plasma Mg levels [58]. Serum Mg is the most common
indicator for assessing Mg status and it is valuable for clinical
purpose, such as rapid assessment of critical changes in Mg
status [59]. However, Mg is an intracellular cation and only 1% of
Mg is in the extracellular ﬂuid; therefore, only about 0.3% of total
body Mg is found in the serum. As a result, some researchers
have considered serum mg levels as a poor indicator of body Mg
status [60]. Moreover, in some people with chronic Mg deﬁ-
ciency, their serum levels might be within the normal range [59].
It could be a possible reason for not ﬁnding a signiﬁcant asso-
ciation between serum Mg and MetS in the present study.
Although in some situations such as being vegetarians (in com-
parisonwith omnivorous), after endurance exercises, and during
the third trimester of pregnancy the serum Mg levels are higher
[61], it is still used as a standard method for assessing the Mg
status in patients, because serum Mg measurement is feasible
and inexpensive [62]. Additionally, the difference in association
between dietary intake and serum levels of Mg in association
with MetS might be because of not taking some confounders
such as other nutrients intake, particularly dietary ﬁber, calcium,
and potassium intake into account. Prospective cohort studies
trying to examine Mg status–MetS relationship, while further
adjusting the association by dietary ﬁber, calcium, and potassium
intake and other nutrients that might possibly affect MetS risk,
are highly recommended.
Although studies are not entirely consistent about the
possible mechanisms, the beneﬁcial effect of Mg on MetS might
be related to its potential effect on MetS components. The pri-
mary aim of the present study was to assess the association
between Mg status and the odds of MetS; as the association for
the components of MetS was not assessed in the majority of
included studies, we were not able to explore this association in
the present work. The beneﬁcial effects of Mg supplementation
on some components of MetS such as hypertension [49], fasting
blood glucose levels, and HDL cholesterol levels [58] have been
revealed in previous systematic reviews and meta-analyses.
Previous studies also reported that low dietary intakes of cal-
cium, Mg, and ﬁber may be associated with insulin resistance
and that supplementation with Mg and calcium improved in-
sulin sensitivity [52,63]. Another study conducted by Paolissoet al. [52] found that Mg supplementation in elderly patients
improves insulin action. Furthermore, it has been also shown
that Mg intake is associated with all components of Met [47],
particularly waist circumference, fasting blood glucose, and HDL
cholesterol level [46]. Mg intake was also inversely linked to the
plasma C-reactive protein concentration and systemic inﬂam-
mation [38].
The nutrition guidelines of the American Diabetes Association
recommendedMg supplementation for diabetic individuals with
low serumMg levels [44]. Although this meta-analysis could not
ﬁnd a strong association between serum Mg and MetS, it has
been indicated that low serum Mg is a signiﬁcant predictor of
dyslipidemia and hypertension [3]. Also, serumMgwas inversely
associated with waist circumference and triacylglycerol (TG)
level [32]. It has been revealed that Mg may regulate serum lipid
level [64], glucose metabolism, and insulin activity [65], and also
has antioxidant [8], anti-inﬂammatory [38], and antihyperten-
sive [66] effects. Several mechanisms have been suggested to
explain the favorable effects of Mg on features of MetS or its
components.
It has been previously suggested that higher Mg intake and
intracellular Mgmight have a role in insulin action and secretion
[16,48] by preserving pancreatic b-cell function via its effect on
calcium homeostasis and oxidative stress [8]. Moreover, Mg is
necessary for the stimulation and transcription of some enzymes
and nuclear proteins that are participating in the glycolytic
pathway, Krebs cycle, and release of insulin. Besides, the insulin
function is completely dependent on Mg, as it is responsible for
the activation of the b-subunit of the insulin receptor, and the
motivation of substrates and proteins in the insulin signaling
pathway [67]. It also regulates cellular glucose metabolism via its
role as a cofactor [68].
Similarly, Mg acts as a cofactor for several critical enzymes
involving lipid metabolism. Mg has been reported to raise HDL
and reduce LDL cholesterol and TG via restraining the action of
lecithin cholesterol acyltransferase [69] and HMG-CoA reduc-
tase and by increasing lipoprotein lipase activity [53]. It has
been assumed that Mg, in the intestine, by forming an unab-
sorbable soap with fatty acids and cholesterol, can decrease
their absorption, reduce energy intake from the diet, and may
have advantages for weight maintenance because of this
capability [59].
Fig. 6. (A) Begg’s funnel plot (with pseudo 95% CI) in log OR versus standard error of log OR for studies that reported the OR of Mg intake. (B) Begg’s funnel plot (with pseudo
95% CI) in MD versus standard error of MD for studies that reported the serum Mg. CI, conﬁdence interval; MD, mean difference; Mg, magnesium; OR, odds ratio.
N. Sarrafzadegan et al. / Nutrition 32 (2016) 409–417 415The present study has several limitations that should be
considered. We could ﬁnd only one prospective cohort study,
and other included studies that tried to ﬁnd the possible asso-
ciation between Mg intake and MetS were cross-sectional in
design. Furthermore, all included studies, which tried to
compare serum levels of Mg between patients with MetS and
healthy controls, were case-control studies. Retrospective
studies including cross-sectional and case-control studies are
prone to recall bias, and also the causal relationship cannot be
inferred from these studies; therefore, prospective studies trying
to ﬁnd these associations are strongly recommended. The
possible mechanisms for the effect of Mg on MetS and its com-
ponents can be tested through further clinical trials with large
sample sizes and follow-up periods. Moreover, although we usedthe highest adjusted model when analyzing the association
between Mg intake and MetS, most of the studies could not
control the dietary factors that are associated with MetS, and it is
difﬁcult to entirely separate the effect of Mg from other dietary
nutrients such as calcium, potassium, and ﬁber. Finally, our
analysis on the mean serum level of Mg in individuals with and
without MetS demonstrated a signiﬁcant heterogeneity among
studies, and we could not ﬁnd the possible source of heteroge-
neity in several subgroup analyses and meta-regression.
Conclusions
The present systematic review and meta-analysis found a
strong inverse association between Mg intake and MetS.
N. Sarrafzadegan et al. / Nutrition 32 (2016) 409–417416Although we found the same association about the relationship
between serum Mg, as a measure of body Mg, and MetS, the
association was highly heterogeneous. Therefore, our results
should be discussed with more caution. Assessing the body Mg
with better indicators of body storage such as Mg retention test,
which shows the stored body Mg, might reveal more accurate
results. Prospective cohort studies trying to examine adjusting
the Mg status–MetS association for other nutrients that might
possibly affect MetS risk are highly recommended.
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